Tumor-Intrinsic Immune Checkpoints: Emerging Implications for Cancer Progression and Immunotherapy

Immune checkpoint pathways have revolutionized cancer therapy, with agents targeting PD-1, CTLA-4, and related molecules achieving durable clinical responses across multiple malignancies. Traditionally, these pathways have been viewed as regulators of immune cell activity, particularly in controlling T-cell activation and exhaustion. However, emerging evidence supports a paradigm shift in which tumor cells themselves express functional immune checkpoint molecules, including both canonical and noncanonical forms. This tumor-intrinsic checkpoint expression extends beyond passive immune evasion and represents an active component of cancer biology. Tumor-expressed checkpoints can promote proliferation, survival, and metastasis through oncogenic signaling pathways, while also shaping the tumor microenvironment via autocrine and paracrine interactions that reinforce immunosuppression. Notably, the functional consequences of these pathways are highly context-dependent, with divergent roles observed across tumor types and molecular backgrounds. These findings have significant clinical implications, including their impact on response heterogeneity to immune checkpoint blockade and their potential as novel therapeutic targets and biomarkers. In this perspective, we discuss the biological and translational relevance of tumor-intrinsic checkpoint signaling, highlight current challenges, and propose future directions for integrating this emerging dimension into precision immuno-oncology.